An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.